The oral route for BPC-157 may be particularly relevant for psoriasis patients who also have gut involvement, as the gut-skin axis is increasingly recognized as a factor in psoriatic disease
[8] Overall, these side effects are short-lived and manageable, often improving by slowing the rate of administration or taking breaks during an intravenous infusion if needed
Furthermore, timing is a critical factor in these research models
compounded formulations with enhanced penetration vehicles offer an alternative for patients who cannot tolerate or prefer to avoid systemic antifungals
Written by Marijn Lewis, PhD Science communication & Nutrition research at Kala Health References Detcheverry, F., Senthil, S., Narayanan, S., & Badhwar, A